Loading…
Shukra Pharmaceuticals (BSE 524632)₹55.87+0.25%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Shukra Pharmaceuticals reported sales of ₹23.99 Cr, up 380.8% from Jun 2025, and net profit of ₹13.03 Cr, up 1,190.1% year on year. For the year to Mar 2026, sales were ₹56.99 Cr and net profit ₹22.06 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|
| Sales | 10.99 | 12.99 | 4.99 | 5.99 | 38.98 | 5.99 | 23.99 |
| Expenses | 7.02 | 6.02 | 4.01 | 6.01 | 12.03 | 6.01 | 4.01 |
| Operating Profit | 4.01 | 7.02 | 1.01 | 0.00 | 27.10 | 1.01 | 19.06 |
| OPM % | 36.9% | 55.0% | 23.9% | −7.0% | 68.9% | 10.9% | 81.0% |
| Other Income | 1.01 | 1.01 | 1.01 | 2.01 | 1.01 | 1.01 | 1.01 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 |
| Profit before tax | 3.99 | 7.99 | 1.01 | 0.00 | 26.98 | 0.00 | 18.01 |
| Tax % | 23.1% | 29.0% | 26.1% | −1,090.0% | 24.1% | 553.0% | 29.1% |
| Net Profit | 3.01 | 5.01 | 1.01 | 2.01 | 20.06 | −2.01 | 13.03 |
| EPS (Rs) | 0.06 | 0.11 | 0.01 | 0.04 | 0.47 | −0.03 | 0.28 |
| Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|
| Sales | 32.99 | 56.99 | 74.95 |
| Expenses | 20.06 | 28.05 | 28.06 |
| Operating Profit | 13.04 | 29.10 | 47.17 |
| OPM % | 39.0% | 50.9% | 62.9% |
| Other Income | 4.02 | 5.02 | 5.04 |
| Interest | 0.99 | 0.99 | 0.00 |
| Depreciation | 3.01 | 3.01 | 4.04 |
| Profit before tax | 12.99 | 29.01 | 44.99 |
| Tax % | 28.0% | 23.0% | — |
| Net Profit | 10.03 | 22.06 | 33.09 |
| EPS (Rs) | 0.21 | 0.49 | 0.76 |
| Dividend payout % | 0.0% | 2.0% | — |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 43.99 | 43.99 |
| Reserves | 18.99 | 46.01 |
| Borrowings | 4.01 | 5.01 |
| Other Liabilities | 20.03 | 22.98 |
| Total Liabilities | 87.02 | 117 |
| Fixed Assets | 19.01 | 22.03 |
| CWIP | 1.99 | 11.98 |
| Investments | 0.00 | 0.00 |
| Other Assets | 65.02 | 83.98 |
| Inventories | 9.92 | 13.85 |
| Trade receivables | 8.75 | 22.88 |
| Cash & equivalents | 12.14 | 5.99 |
| Total Assets | 87.02 | 117 |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Cash from operating activity | 8.02 | 4.01 |
| Cash from investing activity | −0.99 | −13.98 |
| Cash from financing activity | −4.99 | 4.01 |
| Net cash flow | 2.01 | −6.02 |
| Capex | 2.73 | 15.71 |
| Free cash flow | 4.98 | −11.97 |
| CFO / OP % | 92.0% | 19.0% |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Debtor days | 98 | 148 |
| Inventory days | 447 | 320 |
| Days payable | 414 | 232 |
| Cash conversion cycle | 132 | 237 |
| Working capital days | 404 | 353 |
| ROCE % | — | 37.0% |
For the Jun 2026 quarter, Shukra Pharmaceuticals reported sales of ₹23.99 Cr, up 380.8% year on year and net profit of ₹13.03 Cr, up 1,190.1% year on year. The operating margin was 81.0%.
Shukra Pharmaceuticals' sales for the year to Mar 2026 were ₹56.99 Cr; over the last twelve months they were ₹74.95 Cr.
Net profit for the year to Mar 2026 was ₹22.06 Cr, and ₹33.09 Cr over the last twelve months. Earnings per share over the same trailing period were ₹0.76.
Shukra Pharmaceuticals reported borrowings of ₹5.01 Cr at Mar 2026, against cash and equivalents of ₹5.99 Cr.
Cash from operations was ₹4.01 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹11.97 Cr.